MedDay Pharmaceuticals to webcast key opinion leader meeting on new treatment strategies for progressive forms of multiple sclerosis tomorrow

MedDay Pharmaceuticals Announces Full Patient Enrollment for MD1003 Phase III Clinical Trial (SPI2) in Progressive Multiple Sclerosis

MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer

MedDay fait partie des six entreprises prometteuses distinguées dans le cadre du “Trophée des Futures Licornes” décerné par le magazine Challenges

MedDay to Participate in the 7th Joint ECTRIMS – ACTRIMS Meeting in Paris, France

MedDay Pharmaceuticals GmbH to participate at the 90th Congress of the German Society of Neurology in Leipzig, Germany

MedDay Boosts its Research Capabilities with Profilomic Acquisition

MedDay Strengthens its Board with Two Senior Non-Executive Directors

Positive Preclinical Data with MD1003 (high dose pharmaceutical grade biotin) in X-Linked Adrenoleukodystrophy to be presented at European Committee for Treatment and Research in Multiple Sclerosis 2016

MedDay Announces Publication of MD1003 Phase IIb/III Study in the Multiple Sclerosis Journal

MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial

MedDay appoints Catherine Moukheibir as Chairman of its Board of Directors